PT - JOURNAL ARTICLE AU - Sara Ibrahim Taha AU - Sara Farid Samaan AU - Aalaa Kamal Shata AU - Shereen Atef Baioumy AU - Shaimaa Abdalaleem Abdalgeleel AU - Mariam Karam Youssef TI - Baseline Characteristics and Outcomes of 180 Egyptian COVID-19 Patients Admitted to Quarantine Hospitals of Ain Shams University: A Retrospective Comparative Study AID - 10.1101/2021.06.11.21258743 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.11.21258743 4099 - http://medrxiv.org/content/early/2021/07/10/2021.06.11.21258743.short 4100 - http://medrxiv.org/content/early/2021/07/10/2021.06.11.21258743.full AB - Background and study aim COVID-19 mortality, severity, and recovery are major global concerns, but they are still insufficiently understood, particularly in the Middle East. This study focused on evaluating if there was a link between COVID-19 patients’ clinical and laboratory findings at hospital admission and disease severity and mortality.Patients and methods A total of 180 adult Egyptian COVID-19 patients were included in this study then were categorized and compared.Results Of all, 27.8% had severe disease, and 13.9% died during their hospital stay. Diabetes (46.7%), hypertension (36.1%), and chronic obstructive pulmonary disease (COPD) (33.3%) were the most frequent associated co-morbidities. Severe patients and non-survivors were significantly older compared to their corresponding groups. Their neutrophil count, PCT, ESR, C-reactive protein (CRP), AST, ALT, LDH, D-dimer, and ferritin levels were significantly higher (P ≤ 0.05). In contrast, their absolute lymphocyte count was significantly lower (P ≤ 0.05). COPD (OR: 3.294; 95% CI: 1.199-9.053), diabetes (OR: 2.951; 95% CI:1.070- 8.137), ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551), AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991), CT-scoring system (CT-SS) ≥ 17 (OR: 1.205; 95% CI: 1.089-1.334) and lymphocyte count < 1×103/µL (OR: 4.002; 95% CI: 1.537-10.421), were all linked to a higher risk of COVID-19 severity. While mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359), CT-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482) and AST ≥ 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661).Conclusions Clinical and laboratory data of COVID-19 patients at their hospital admission may aid in identifying early risk factors for severe illness and a high mortality rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ain Shams University Faculty of Medicine Research Ethics Committee (REC)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon requestACE-2Angiotensin-converting enzyme-2COPDChronic obstructive pulmonary diseaseCOVID-19Coronavirus disease 2019CT-SSCT-scoring systemRT- PCRReverse transcription-polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome corona virus 2WHOWorld Health Organization.